Toxic Exposures Translational Research Award | HT942524TERPTRA

Opportunity Information: Apply for HT942524TERPTRA

The Toxic Exposures Translational Research Award (TERP TRA), funding opportunity number HT942524TERPTRA, is a discretionary federal grant program offered by the Department of the Army through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It falls under the Science and Technology and other Research and Development funding activity category (CFDA 12.420). The program was created on June 26, 2024, and the original application closing date is November 7, 2024. Eligibility is listed as unrestricted, meaning the opportunity is broadly open to applicants rather than being limited to a narrow set of institution types.

The core purpose of the FY24 TERP TRA is to fund translational research focused on military-related toxic exposures, specifically work that moves strong scientific ideas closer to real-world clinical use. The emphasis is not on basic discovery for its own sake, but on accelerating the path from promising research findings to practical outcomes that can be used in health care settings. The notice makes clear that desired end products can include health care products (for example, diagnostics or therapeutic approaches), interventions (such as prevention or treatment strategies), technologies (tools or platforms that enable better detection, monitoring, or care), and/or clinical practice guidelines (evidence-backed recommendations that clinicians can apply in practice).

In this program, translational research is framed as an intentional integration of basic science and clinical observations. In other words, projects should connect mechanistic or laboratory insights with patient-centered or clinically relevant data, and they should be designed in a way that makes the eventual clinical application credible and achievable. A key expectation is bidirectional, or reciprocal, flow of information between the basic and clinical sides of the work. That could look like clinical observations shaping the laboratory experiments and target selection, while laboratory findings inform clinical hypotheses, biomarker development, patient stratification approaches, or the design of future clinical studies. The application is expected to demonstrate this back-and-forth connection as a concrete part of the research plan, rather than treating basic and clinical components as separate, loosely related activities.

The announcement also notes that New Approach Methodologies (NAMs) may be used. While the opportunity text does not list specific NAM examples, the intent is generally to support modern approaches that can improve relevance, reduce uncertainty, or speed translation, such as advanced in vitro human-relevant systems, computational and modeling approaches, or other innovative methods that strengthen the link between exposure science, biological effect, and clinical decision-making. The practical takeaway is that applicants can incorporate these methods when they help bridge the gap between early-stage findings and clinical implementation.

Finally, the opportunity anticipates making approximately six awards. The public summary does not specify an award ceiling amount, so prospective applicants would need to consult the full funding announcement or related guidance for budget constraints, allowable costs, and other requirements. Overall, the TERP TRA is positioned as a translational pipeline accelerator: it is meant to take military toxic exposure research that is already promising and push it toward deliverables that can realistically influence clinical care, tools, or guidelines.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "Toxic Exposures Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-06-26.
• Applicants must submit their applications by 2024-11-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524TERPTRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: